XRP44X | CAS#729605-21-4 | Elk-3 inhibitor

MedKoo Cat#: 563553 | Name: XRP44X

Description:

WARNING: This product is for research use only, not for human or veterinary use.

XRP44X is a potent inhibitor of the Ras/Erk signaling pathway, specifically targeting the transcription factor Elk3. It exhibits an IC₅₀ of approximately 10 nM in inhibiting Net phosphorylation upstream of Erk1/2 activation. Beyond its effects on the Ras/Erk pathway, XRP44X also acts as a microtubule depolymerizing agent, leading to G₂-M cell cycle arrest and suppression of growth in various cell types, with an IC₅₀ around 2 nM.

Chemical Structure

XRP44X

CAS#729605-21-4

Theoretical Analysis

MedKoo Cat#: 563553

Name: XRP44X

CAS#: 729605-21-4

Chemical Formula: C21H21ClN4O

Exact Mass: 380.1404

Molecular Weight: 380.87

Elemental Analysis: C, 66.22; H, 5.56; Cl, 9.31; N, 14.71; O, 4.20

Price and Availability

Size	Price	Availability
100mg	USD 450.00	2 Weeks
200mg	USD 850.00	2 Weeks
500mg	USD 1,650.00	2 Weeks
1g	USD 2,950.00	2 Weeks
2g	USD 4,950.00	2 Weeks
5g	USD 7,450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

XRP44X; XRP-44X; XRP 44X; XRP-44-X; XRP 44 X;

IUPAC/Chemical Name

1-(3-Chlorophenyl)-4-[(3-methyl-1-phenyl-1H-pyrazol-5-yl)carbonyl]piperazine

InChi Key

NPHPNBGYPKBDDB-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H21ClN4O/c1-16-14-20(26(23-16)18-7-3-2-4-8-18)21(27)25-12-10-24(11-13-25)19-9-5-6-17(22)15-19/h2-9,14-15H,10-13H2,1H3

SMILES Code

O=C(N1CCN(C2=CC=CC(Cl)=C2)CC1)C3=CC(C)=NN3C4=CC=CC=C4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 380.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Wang C, Shi L, Yang S, Chang J, Liu W, Zeng J, Meng J, Zhang R, Xing D. Research progress on antitumor activity of XRP44X and analogues as microtubule targeting agents. Front Chem. 2023 Mar 1;11:1096666. doi: 10.3389/fchem.2023.1096666. PMID: 36936533; PMCID: PMC10014799. 2: Tezuka T, Azuma M, Ogawa H, Kondo M, Uehara H, Aono Y, Hanibuchi M, Nishioka Y. A RAS inhibitor reduces allergic airway remodeling via regulating IL-33-derived type 2 innate lymphoid cells. Exp Lung Res. 2021 Nov;47(9):451-463. doi: 10.1080/01902148.2021.1999536. Epub 2021 Nov 5. PMID: 34739349. 3: Wang C, Li Y, Liu Z, Wang Z, Liu Z, Man S, Zhang Y, Bao K, Wu Y, Guan Q, Zuo D, Zhang W. Design, synthesis and biological evaluation of 1-Aryl-5-(4-arylpiperazine-1-carbonyl)-1H-tetrazols as novel microtubule destabilizers. J Enzyme Inhib Med Chem. 2021 Dec;36(1):549-560. doi: 10.1080/14756366.2020.1759582. PMID: 33522315; PMCID: PMC8759721. 4: Wang C, Wang Z, Gao M, Li Y, Zhang Y, Bao K, Wu Y, Guan Q, Zuo D, Zhang W. Design, synthesis and anticancer activity of 5-aryl-4-(4-arylpiperazine-1-carbonyl)-1,2,3-thiadiazoles as microtubule- destabilizing agents. Bioorg Chem. 2021 Jan;106:104199. doi: 10.1016/j.bioorg.2020.104199. Epub 2020 Aug 26. PMID: 33317837. 5: Kim KS, Park KS. XRP44X Enhances the Cytotoxic Activity of Natural Killer Cells by Activating the c-JUN N-Terminal Kinase Signaling Pathway. Dev Reprod. 2020 Mar;24(1):53-62. doi: 10.12717/DR.2020.24.1.53. Epub 2020 Mar 31. PMID: 32411918; PMCID: PMC7201060. 6: Li TZ, Kim SM, Hur W, Choi JE, Kim JH, Hong SW, Lee EB, Lee JH, Yoon SK. Elk-3 Contributes to the Progression of Liver Fibrosis by Regulating the Epithelial-Mesenchymal Transition. Gut Liver. 2017 Jan 15;11(1):102-111. doi: 10.5009/gnl15566. PMID: 27538444; PMCID: PMC5221867. 7: Semenchenko K, Wasylyk C, Cheung H, Tourrette Y, Maas P, Schalken JA, van der Pluijm G, Wasylyk B. XRP44X, an Inhibitor of Ras/Erk Activation of the Transcription Factor Elk3, Inhibits Tumour Growth and Metastasis in Mice. PLoS One. 2016 Jul 18;11(7):e0159531. doi: 10.1371/journal.pone.0159531. PMID: 27427904; PMCID: PMC4948895. 8: Chen J, Sun WL, Wasylyk B, Wang YP, Zheng H. c-Jun N-terminal kinase mediates microtubule-depolymerizing agent-induced microtubule depolymerization and G2/M arrest in MCF-7 breast cancer cells. Anticancer Drugs. 2012 Jan;23(1):98-107. doi: 10.1097/CAD.0b013e32834bc978. PMID: 21968419. 9: Wasylyk C, Zheng H, Castell C, Debussche L, Multon MC, Wasylyk B. Inhibition of the Ras-Net (Elk-3) pathway by a novel pyrazole that affects microtubules. Cancer Res. 2008 Mar 1;68(5):1275-83. doi: 10.1158/0008-5472.CAN-07-2674. PMID: 18316589.